Mineralys Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 12.61 million compared to USD 7.57 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 1.48 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.04 USD | +2.82% | -4.29% | +40.00% |
06-20 | Mineralys Therapeutics Insider Sold Shares Worth $592,022, According to a Recent SEC Filing | MT |
06-14 | Mineralys Therapeutics, Inc. Announces Changes to its Board | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.00% | 598M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- MLYS Stock
- News Mineralys Therapeutics, Inc.
- Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023